The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
Background: Increased understanding of the molecular causes of disease has begun to fulfill the promise of precision medicine with the development of targeted drugs, particularly for serious diseases with unmet needs. The drug approval regulatory process is a critical component to the continued grow...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/1/45 |
| _version_ | 1797411804088893440 |
|---|---|
| author | Ariel Kantor Susanne B. Haga |
| author_facet | Ariel Kantor Susanne B. Haga |
| author_sort | Ariel Kantor |
| collection | DOAJ |
| description | Background: Increased understanding of the molecular causes of disease has begun to fulfill the promise of precision medicine with the development of targeted drugs, particularly for serious diseases with unmet needs. The drug approval regulatory process is a critical component to the continued growth of precision medicine drugs and devices. To facilitate the development and approval process of drugs for serious unmet needs, four expedited approval programs have been developed in the US: priority review, accelerated approval, fast track, and breakthrough therapy programs. Methods: To determine if expedited approval programs are fulfilling the intended goals, we reviewed drug approvals by the US Food and Drug Administration (FDA) between 2011 and 2017 for new molecular entities (NMEs). Results: From 2011 through 2017, the FDA approved 250 NMEs, ranging from 27 approvals in 2013 to 46 in 2017. The NME approvals spanned 22 different disease classes; almost one-third of all NMEs were for oncology treatments. Conclusions: As these pathways are utilized more, additional legislative changes may be needed to re-align incentives to promote continued development of innovative drugs for serious unmet needs in a safe, efficacious, and affordable manner. |
| first_indexed | 2024-03-09T04:51:32Z |
| format | Article |
| id | doaj.art-fe8f62f1f525425ca770fbfae4d72d09 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T04:51:32Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-fe8f62f1f525425ca770fbfae4d72d092023-12-03T13:10:49ZengMDPI AGJournal of Personalized Medicine2075-44262021-01-011114510.3390/jpm11010045The Potential Benefit of Expedited Development and Approval Programs in Precision MedicineAriel Kantor0Susanne B. Haga1Center for Applied Genomic & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USACenter for Applied Genomic & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USABackground: Increased understanding of the molecular causes of disease has begun to fulfill the promise of precision medicine with the development of targeted drugs, particularly for serious diseases with unmet needs. The drug approval regulatory process is a critical component to the continued growth of precision medicine drugs and devices. To facilitate the development and approval process of drugs for serious unmet needs, four expedited approval programs have been developed in the US: priority review, accelerated approval, fast track, and breakthrough therapy programs. Methods: To determine if expedited approval programs are fulfilling the intended goals, we reviewed drug approvals by the US Food and Drug Administration (FDA) between 2011 and 2017 for new molecular entities (NMEs). Results: From 2011 through 2017, the FDA approved 250 NMEs, ranging from 27 approvals in 2013 to 46 in 2017. The NME approvals spanned 22 different disease classes; almost one-third of all NMEs were for oncology treatments. Conclusions: As these pathways are utilized more, additional legislative changes may be needed to re-align incentives to promote continued development of innovative drugs for serious unmet needs in a safe, efficacious, and affordable manner.https://www.mdpi.com/2075-4426/11/1/45regulationdrugsprecision medicineexpedited revieworphan drugs |
| spellingShingle | Ariel Kantor Susanne B. Haga The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine Journal of Personalized Medicine regulation drugs precision medicine expedited review orphan drugs |
| title | The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine |
| title_full | The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine |
| title_fullStr | The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine |
| title_full_unstemmed | The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine |
| title_short | The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine |
| title_sort | potential benefit of expedited development and approval programs in precision medicine |
| topic | regulation drugs precision medicine expedited review orphan drugs |
| url | https://www.mdpi.com/2075-4426/11/1/45 |
| work_keys_str_mv | AT arielkantor thepotentialbenefitofexpediteddevelopmentandapprovalprogramsinprecisionmedicine AT susannebhaga thepotentialbenefitofexpediteddevelopmentandapprovalprogramsinprecisionmedicine AT arielkantor potentialbenefitofexpediteddevelopmentandapprovalprogramsinprecisionmedicine AT susannebhaga potentialbenefitofexpediteddevelopmentandapprovalprogramsinprecisionmedicine |